Semaglutide microdosing for weight control in people living with HIV
Official title: Incretin Microdosing for Cardiometabolic Health in People With HIV: The REINFORCE Trial
Run by The University of Texas Health Science Center, Houston · NCT07325500 · Data updated 2026-11-12
Small weekly doses of semaglutide will be tried to see if they prevent weight regain in adults living with HIV after an initial weight-loss induction.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 30 (estimated) |
| Sponsor | The University of Texas Health Science Center, Houston Academic / other |
| Locations | 1 site (Houston, Texas) |
| Status | Recruiting |
| Started | February 12, 2026 |
| Main results expected | May 31, 2028 |
| Study ends | June 30, 2029 |
| Registry record updated | February 18, 2026 |
| Trial ID | NCT07325500 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults living with HIV who are on stable ART with viral suppression and have BMI ≥30 kg/m2 (or ≥27 kg/m2 with a weight-related comorbidity) and can attend in-person visits are the intended candidates.
✕Probably not a fit
People with uncontrolled HIV, recent unexplained weight change, weight ≥400 pounds (DXA limit), recent ART changes, or those unable to maintain stable concomitant medications or attend study visits are unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Adults with HIV on stable antiretroviral therapy and with obesity will complete a 12-week semaglutide induction with dose escalation up to 2 mg weekly. After induction, participants are assigned to continued semaglutide microdosing (0.5 mg weekly) or no additional semaglutide for 48 weeks, with regular visits to track weight, waist circumference, BMI and tolerability. The primary outcome is the rate of weight regain after induction; secondary outcomes include tolerability and changes in body composition over the 60-week period. The trial is led by The University of Texas Health Science Center at Houston with collaboration from NIDDK, University of Colorado Denver Anschutz, and Massachusetts General Hospital.
Why it matters
Potential benefit: If successful, this approach could help people living with HIV keep off weight after initial weight loss and improve long-term cardiometabolic health.
How similar studies have gone: Large semaglutide trials in the general population have shown substantial weight loss, but the strategy of low-dose maintenance to prevent regain in people with HIV is relatively novel and less well studied.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Confirmed human immunodeficiency virus type 1 (HIV-1) * On antiretroviral therapy (ART) for greater than or equal to 24 weeks prior to entry and no change in regimen in the 12 weeks prior to entry or planned change for the study duration * HIV-1 ribonucleic acid (RNA) \<200 copies/mL at screening * BMI greater than or equal to 30 kg/m2 or greater than or equal to 27 kg/m2 if also with greater than or equal to 1 weight-related comorbidity * If taking anti-inflammatory or blood-pressure-/lipid-/glucose-lowering medications, no change in dose for greater than or equal to 12 weeks prior to entry and no plans to dose escalate for the study duration * All participants must be willing and able to provide written informed consent and undergo all required study procedures Exclusion Criteria: * Weight greater than or equal to 400 pounds \[due to dual X-ray absorptiometry (DXA) machine limitations\] or unexplained weight change greater than or equal to 5% in the 12 weeks prior to entry * Diagnosis of or on treatment for diabetes mellitus (stable metformin dosing for pre-diabetes not excluded) * Current or planned use of medications for the treatment of obesity, or medications likely to cause significant changes in weight, during the study period * Plans to newly engage in formal, intensive physical activity or diet (such as ketogenic or very low carbohydrate) programs during the study period * Active eating disorder * Use of human growth hormone, tesamorelin or anabolic steroids \<12 weeks prior to entry, unless on a stable dose for \>24 weeks prior to entry, or plans to start any of these medications while on study * Active, severe delayed gastric emptying * Prior bariatric surgery or major gastric surgery or plans for weight reduction surgery while on study * Known retinopathy * Personal or first-degree relative history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 * Untreated, poorly controlled or previously undiagnosed thyroid disease * Chronic pancreatitis * Known allergy/sensitivity to Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) * Poorly controlled or previously undiagnosed thyroid disease, defined as thyroid-stimulating hormone (TSH) \<0.5 or \>10 milli-international units per liter (mIU/L) at screening * Active drug or alcohol use that, in the opinion of the investigator, would interfere with adherence to study requirements * Pregnancy, nursing or plans for either during the study period * Use of planned use of any immunomodulatory therapy HIV vaccine, investigational therapy or tumor necrosis factor (TNF-α) therapy during the study period * Current serious illness requiring systemic treatment and/or hospitalization, in the opinion of site investigator
Where it's running
-
The University of Texas Health Science Center at Houston
Houston, Texas, United States Recruiting
Study contacts
- Principal investigator: Jordan Lake, MD, MSc — The University of Texas Health Science Center, Houston
- Study coordinator: Jordan E Lake, MD, MSc
- Email: Jordan.E.Lake@uth.tmc.edu
- Phone: 713-500-6767
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Pregnant women weight-management support via an app and care model
Aims to try a smartphone-based weight-management program plus professional support for pregnant women to see if it helps manage gestational weight and promote healthy behaviors.
-
Time-restricted eating to help keep weight off
This 12-month randomized test will see if eating only within a 10-hour daily window helps adults who recently lost weight keep it off and limit fat regain.
-
Digital support for pregnant women with a BMI of 25 or higher
This study is testing a digital care guide to see if it can help pregnant women with a higher BMI manage their weight and improve their mental health during pregnancy.
-
High-intensity interval exercise to support brain activity and weight maintenance
This trial will test whether a 12-week high-intensity interval training (HIIT) program changes brain activity and helps with weight maintenance in adults 18–70, including people who regained weight after bariatric surgery.
-
Evaluating tirzepatide for treating obesity in adolescents
This study is testing if tirzepatide can help teenagers with obesity lose weight and improve their heart health while they follow a healthy eating and exercise program.
-
Comparing two methods for weight loss after gastric bypass
This study is testing two different ways to help people who have gained weight after gastric bypass surgery lose weight again, to see which method works better and is safer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.